268 related articles for article (PubMed ID: 20713596)
41. Vertical Transmission of Hepatitis C Virus: Variable Transmission Bottleneck and Evidence of Midgestation
Fauteux-Daniel S; Larouche A; Calderon V; Boulais J; Béland C; Ransy DG; Boucher M; Lamarre V; Lapointe N; Boucoiran I; Le Campion A; Soudeyns H
J Virol; 2017 Dec; 91(23):. PubMed ID: 28931691
[TBL] [Abstract][Full Text] [Related]
42. New therapeutic options for HCV infection in the monoclonal antibody era.
Sautto GA; Diotti RA; Clementi M
New Microbiol; 2012 Oct; 35(4):387-97. PubMed ID: 23109006
[TBL] [Abstract][Full Text] [Related]
43. A Novel Approach To Display Structural Proteins of Hepatitis C Virus Quasispecies in Patients Reveals a Key Role of E2 HVR1 in Viral Evolution.
Tong Y; Li Q; Li R; Xu Y; Pan Y; Niu J; Zhong J
J Virol; 2020 Aug; 94(17):. PubMed ID: 32554700
[TBL] [Abstract][Full Text] [Related]
44. Replication-competent recombinant vesicular stomatitis virus encoding hepatitis C virus envelope proteins.
Tani H; Komoda Y; Matsuo E; Suzuki K; Hamamoto I; Yamashita T; Moriishi K; Fujiyama K; Kanto T; Hayashi N; Owsianka A; Patel AH; Whitt MA; Matsuura Y
J Virol; 2007 Aug; 81(16):8601-12. PubMed ID: 17553880
[TBL] [Abstract][Full Text] [Related]
45. Mouse monoclonal antibody towards e1 specific epitope blocks viral entry and intracellular viral replication in vitro.
Tabll AA; Moustafa RI; El Abd YS; Bader El Din NG; El-Shenawy R; Yousef H; Hussein M; Dawood RM; Omran MH; El-Awady MK
J Immunoassay Immunochem; 2014; 35(1):60-73. PubMed ID: 24063617
[TBL] [Abstract][Full Text] [Related]
46. Extra-epitopic hepatitis C virus polymorphisms confer resistance to broadly neutralizing antibodies by modulating binding to scavenger receptor B1.
El-Diwany R; Cohen VJ; Mankowski MC; Wasilewski LN; Brady JK; Snider AE; Osburn WO; Murrell B; Ray SC; Bailey JR
PLoS Pathog; 2017 Feb; 13(2):e1006235. PubMed ID: 28235087
[TBL] [Abstract][Full Text] [Related]
47. Standardized Method for the Study of Antibody Neutralization of HCV Pseudoparticles (HCVpp).
Bailey JR; Urbanowicz RA; Ball JK; Law M; Foung SKH
Methods Mol Biol; 2019; 1911():441-450. PubMed ID: 30593644
[TBL] [Abstract][Full Text] [Related]
48. Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection.
Lavillette D; Morice Y; Germanidis G; Donot P; Soulier A; Pagkalos E; Sakellariou G; Intrator L; Bartosch B; Pawlotsky JM; Cosset FL
J Virol; 2005 May; 79(10):6023-34. PubMed ID: 15857988
[TBL] [Abstract][Full Text] [Related]
49. Unexpected maintenance of hepatitis C viral diversity following liver transplantation.
Gray RR; Strickland SL; Veras NM; Goodenow MM; Pybus OG; Lemon SM; Fried MW; Nelson DR; Salemi M
J Virol; 2012 Aug; 86(16):8432-9. PubMed ID: 22623804
[TBL] [Abstract][Full Text] [Related]
50. Specialization of Hepatitis C Virus Envelope Glycoproteins for B Lymphocytes in Chronically Infected Patients.
Douam F; Bobay LM; Maurin G; Fresquet J; Calland N; Maisse C; Durand T; Cosset FL; Féray C; Lavillette D
J Virol; 2016 Jan; 90(2):992-1008. PubMed ID: 26537674
[TBL] [Abstract][Full Text] [Related]
51. Escape of Hepatitis C Virus from Epitope I Neutralization Increases Sensitivity of Other Neutralization Epitopes.
Gu J; Hardy J; Boo I; Vietheer P; McCaffrey K; Alhammad Y; Chopra A; Gaudieri S; Poumbourios P; Coulibaly F; Drummer HE
J Virol; 2018 May; 92(9):. PubMed ID: 29467319
[TBL] [Abstract][Full Text] [Related]
52. Virus-neutralizing antibodies to hepatitis C virus.
Wahid A; Dubuisson J
J Viral Hepat; 2013 Jun; 20(6):369-76. PubMed ID: 23647953
[TBL] [Abstract][Full Text] [Related]
53. Tracking hepatitis C virus quasispecies major and minor variants in symptomatic and asymptomatic liver transplant recipients.
Gretch DR; Polyak SJ; Wilson JJ; Carithers RL; Perkins JD; Corey L
J Virol; 1996 Nov; 70(11):7622-31. PubMed ID: 8892882
[TBL] [Abstract][Full Text] [Related]
54. N-glycosylation-mutated HCV envelope glycoprotein complex enhances antigen-presenting activity and cellular and neutralizing antibody responses.
Ren Y; Min YQ; Liu M; Chi L; Zhao P; Zhang XL
Biochim Biophys Acta; 2016 Aug; 1860(8):1764-75. PubMed ID: 26278021
[TBL] [Abstract][Full Text] [Related]
55. Entry of hepatitis C virus pseudotypes into primary human hepatocytes by clathrin-dependent endocytosis.
Codran A; Royer C; Jaeck D; Bastien-Valle M; Baumert TF; Kieny MP; Pereira CA; Martin JP
J Gen Virol; 2006 Sep; 87(Pt 9):2583-2593. PubMed ID: 16894197
[TBL] [Abstract][Full Text] [Related]
56. Development of an effective single-chain variable fragment recognizing a novel epitope in the hepatitis C virus E2 protein that restricts virus entry into hepatocytes.
Das S; Behera P; Shewale DJ; Bodele J; Das S; Karande AA
Arch Virol; 2024 Apr; 169(5):112. PubMed ID: 38683226
[TBL] [Abstract][Full Text] [Related]
57. Therapeutic control of hepatitis C virus: the role of neutralizing monoclonal antibodies.
Keck ZY; Machida K; Lai MM; Ball JK; Patel AH; Foung SK
Curr Top Microbiol Immunol; 2008; 317():1-38. PubMed ID: 17990788
[TBL] [Abstract][Full Text] [Related]
58. Hepatitis C virus (HCV)-induced immunoglobulin hypermutation reduces the affinity and neutralizing activities of antibodies against HCV envelope protein.
Machida K; Kondo Y; Huang JY; Chen YC; Cheng KT; Keck Z; Foung S; Dubuisson J; Sung VM; Lai MM
J Virol; 2008 Jul; 82(13):6711-20. PubMed ID: 18417597
[TBL] [Abstract][Full Text] [Related]
59. Hepatitis C virus resistance to broadly neutralizing antibodies measured using replication-competent virus and pseudoparticles.
Wasilewski LN; Ray SC; Bailey JR
J Gen Virol; 2016 Nov; 97(11):2883-2893. PubMed ID: 27667373
[TBL] [Abstract][Full Text] [Related]
60. Hepatitis C virus entry.
Zeisel MB; Felmlee DJ; Baumert TF
Curr Top Microbiol Immunol; 2013; 369():87-112. PubMed ID: 23463198
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
